LTC2379069I2 - S1p receptoriaus agonisto dozavimas - Google Patents

S1p receptoriaus agonisto dozavimas

Info

Publication number
LTC2379069I2
LTC2379069I2 LTPA2020513C LTPA2020513C LTC2379069I2 LT C2379069 I2 LTC2379069 I2 LT C2379069I2 LT PA2020513 C LTPA2020513 C LT PA2020513C LT PA2020513 C LTPA2020513 C LT PA2020513C LT C2379069 I2 LTC2379069 I2 LT C2379069I2
Authority
LT
Lithuania
Prior art keywords
receptor agonist
agonist dosage
dosage
receptor
agonist
Prior art date
Application number
LTPA2020513C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41435196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2379069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LTPA2020513I1 publication Critical patent/LTPA2020513I1/lt
Publication of LTC2379069I2 publication Critical patent/LTC2379069I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
LTPA2020513C 2008-12-22 2020-06-23 S1p receptoriaus agonisto dozavimas LTC2379069I2 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967308P 2008-12-22 2008-12-22
EP09167209 2009-08-04
PCT/EP2009/067618 WO2010072703A1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist
EP09793546.4A EP2379069B1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist

Publications (2)

Publication Number Publication Date
LTPA2020513I1 LTPA2020513I1 (lt) 2020-07-27
LTC2379069I2 true LTC2379069I2 (lt) 2022-05-25

Family

ID=41435196

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2020513C LTC2379069I2 (lt) 2008-12-22 2020-06-23 S1p receptoriaus agonisto dozavimas

Country Status (35)

Country Link
US (2) US8492441B2 (lt)
EP (1) EP2379069B1 (lt)
JP (2) JP5657565B2 (lt)
KR (1) KR101660555B1 (lt)
CN (2) CN102264363A (lt)
AR (1) AR074825A1 (lt)
AU (1) AU2009331582B2 (lt)
BR (1) BRPI0923213A2 (lt)
CA (3) CA2747992C (lt)
CY (2) CY1116321T1 (lt)
DK (1) DK2379069T3 (lt)
ES (1) ES2538413T3 (lt)
FR (1) FR20C1022I2 (lt)
HK (1) HK1159524A1 (lt)
HR (1) HRP20150567T1 (lt)
HU (2) HUE026400T2 (lt)
IL (2) IL294658A (lt)
JO (1) JO3044B1 (lt)
LT (1) LTC2379069I2 (lt)
LU (1) LUC00160I2 (lt)
MA (1) MA32907B1 (lt)
MX (2) MX367667B (lt)
NL (1) NL301046I2 (lt)
NO (1) NO2020017I1 (lt)
NZ (1) NZ593427A (lt)
PL (1) PL2379069T3 (lt)
PT (1) PT2379069E (lt)
RU (1) RU2561681C2 (lt)
SG (1) SG171888A1 (lt)
SI (1) SI2379069T1 (lt)
TN (1) TN2011000281A1 (lt)
TW (1) TWI472327B (lt)
UY (1) UY32350A (lt)
WO (1) WO2010072703A1 (lt)
ZA (1) ZA201104102B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785484B2 (en) 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
SI2307007T1 (sl) * 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
JP2013525469A (ja) * 2010-05-06 2013-06-20 ノバルティス アーゲー ジアリールスルフィド誘導体の投与レジメン
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
PL2661261T3 (pl) 2011-01-07 2020-01-31 Novartis Ag Formulacje immunosupresyjne
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
RU2014120411A (ru) * 2011-10-21 2015-11-27 Новартис Аг Схема приема модулятора или агониста рецептора s1p
CA2895172C (en) 2012-08-17 2020-08-18 Actelion Pharmaceuticals Ltd Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process
EP3647783B1 (en) * 2013-04-04 2022-12-21 Novartis AG Identifying patient response to s1p receptor modulator administration
SI3129006T1 (sl) * 2014-04-10 2021-08-31 Novartis Ag Formulacija imunosupresivov
RU2715734C2 (ru) 2014-04-10 2020-03-03 Новартис Аг Схема дозирования модулятора s1p с немедленным высвобождением
PT3256125T (pt) 2014-12-11 2022-05-06 Actelion Pharmaceuticals Ltd Regime de dosagem para ponesimod, um agonista de recetor s1p1 seletivo
MX2021011472A (es) * 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company OXIME ETHER COMPOUNDS
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
CA3074416A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
CA3207440A1 (en) 2021-02-08 2022-08-11 Jimin Lee Amiselimod for preventing, treating, or ameliorating ulcerative colitis
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176819A (zh) * 1997-09-03 1998-03-25 王树生 一种解酒饮料及其制备方法
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
JP5547865B2 (ja) * 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
WO2005058316A1 (ja) 2003-12-17 2005-06-30 Dainippon Sumitomo Pharma Co., Ltd. 合剤および併用剤
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006058316A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
WO2008072056A1 (en) * 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
PL2952177T3 (pl) * 2007-10-12 2021-07-19 Novartis Ag Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p)

Also Published As

Publication number Publication date
KR20110106399A (ko) 2011-09-28
PT2379069E (pt) 2015-07-03
TW201028147A (en) 2010-08-01
LUC00160I1 (lt) 2020-06-19
JP2012513378A (ja) 2012-06-14
LUC00160I2 (lt) 2021-07-06
NL301046I2 (nl) 2020-07-29
JP5657565B2 (ja) 2015-01-21
HRP20150567T1 (hr) 2015-08-14
IL213347A0 (en) 2011-07-31
CN105213372A (zh) 2016-01-06
EP2379069B1 (en) 2015-03-04
WO2010072703A1 (en) 2010-07-01
LTPA2020513I1 (lt) 2020-07-27
MX367667B (es) 2019-08-30
SI2379069T1 (sl) 2015-07-31
CN102264363A (zh) 2011-11-30
JP5941110B2 (ja) 2016-06-29
MA32907B1 (fr) 2011-12-01
US8492441B2 (en) 2013-07-23
NL301046I1 (nl) 2020-06-17
JO3044B1 (ar) 2016-09-05
NO2020017I1 (no) 2020-06-17
CY2020014I2 (el) 2020-11-25
JP2015038097A (ja) 2015-02-26
AU2009331582B2 (en) 2014-03-13
HK1159524A1 (en) 2012-08-03
KR101660555B1 (ko) 2016-09-27
TWI472327B (zh) 2015-02-11
AR074825A1 (es) 2011-02-16
BRPI0923213A2 (pt) 2016-01-26
HUE026400T2 (en) 2016-06-28
CA3105857C (en) 2023-08-01
HUS2000017I1 (hu) 2020-07-28
CY1116321T1 (el) 2017-02-08
RU2561681C2 (ru) 2015-08-27
SG171888A1 (en) 2011-07-28
FR20C1022I2 (fr) 2021-06-11
IL294658A (en) 2022-09-01
UY32350A (es) 2010-04-30
CA2981830A1 (en) 2010-07-01
CA3105857A1 (en) 2010-07-01
ZA201104102B (en) 2012-02-29
AU2009331582A1 (en) 2011-06-30
US20130281712A1 (en) 2013-10-24
US20110039818A1 (en) 2011-02-17
EP2379069A1 (en) 2011-10-26
MX2011006625A (es) 2011-09-28
CY2020014I1 (el) 2020-11-25
ES2538413T3 (es) 2015-06-19
IL213347B (en) 2019-11-28
FR20C1022I1 (lt) 2020-07-31
CA2747992A1 (en) 2010-07-01
NZ593427A (en) 2013-11-29
PL2379069T3 (pl) 2015-08-31
TN2011000281A1 (en) 2012-12-17
DK2379069T3 (en) 2015-06-08
CA2747992C (en) 2017-11-07

Similar Documents

Publication Publication Date Title
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
CY2020036I1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
DK2381986T3 (da) Lægemiddeladministrationsanordning
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
BRPI0810374A2 (pt) Inibidores específicos do pdgfrbeta
BRPI0920521A2 (pt) combinação farmacêutica
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
DK2274030T4 (da) Lægemiddelafgivelsesanordning
DK2326651T3 (da) Buprenorphinanaloger
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0918064A2 (pt) distribuidor de substância
BR112013002096A2 (pt) compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
BRPI0915781A2 (pt) oxazolopiridimas como agonista do receptor edg-1
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
DK2271618T3 (da) Farmaceutiske forbindelser
DK2131818T3 (da) Ny doseringsform
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
IT1390848B1 (it) Composti farmaceutici
SMT201500123B (it) Dosaggio unitario di apadenoson
DK2257534T3 (da) 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
BRPI0909764A2 (pt) compostos terapêuticos